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Purpose: To assess the outcomes of pars plana vitrectomy for the treatment of malignant 
glaucoma in patients with and without previous filtration surgery.
Patients and methods: Data of 15 patients developing malignant glaucoma after trabeculec-
tomy (60%) or following ophthalmic interventions other than filtration surgery (40%) were 
recorded retrospectively. Pars plana vitrectomy was performed in case of failed medical or laser 
treatment recreating the normal pathway of aqueous humor. The main outcome measures were 
the postoperative intraocular pressure (IOP), the frequency of complications, and success rate 
based on the following criteria: IOP reduction by $20% and to #21 mmHg (definition one) 
or an IOP , 18 mmHg (definition two) with (qualified success) and without (complete success) 
glaucoma medication.
Results: Vitrectomy reduced IOP from baseline in eyes with and without previous trabeculec-
tomy during a median follow-up of 16.4 months (range 7 days to 58 months); although the 
majority of patients required glaucoma medication to reach desired IOP. The complete success 
rates were 11% (both definitions) for patients with filtering blebs and none of the patients  without 
previous trabeculectomy had complete success at the 12-month visit. Complications were few 
and included transient shallowing of the anterior chamber, choroidal detachment, corneal 
decompensation, filtering bleb failure, and need for further IOP-lowering procedures.
Conclusion: Pars plana vitrectomy is equally effective for malignant glaucoma caused by 
trabeculectomy or interventions other than filtration surgery, although IOP-lowering medication 
is necessary in nearly all cases to maintain target IOP.
Keywords: ciliolenticular block glaucoma, malignant glaucoma, pars plana vitrectomy, 
trabeculectomy
Introduction
Malignant glaucoma is a rare but serious condition of secondary angle closure mostly 
seen after filtration surgery, but it may also occur spontaneously.1 It has also been 
described after laser iridotomy,2 laser capsulotomy,3 cataract surgery,4 topical miotic 
therapy,5 and blunt trauma.6 Some basic mechanisms of ciliolenticular block glaucoma 
are poorly understood. Lens disproportion and lens–ciliary body apposition in small 
eyes and anterior hyaloid changes with increased hydraulic resistance are supposed 
to be major pathophysiological factors.7 Besides these factors, poor vitreous flow and 
a tendency towards expansion of the choroidal volume in small eyes with angle clo-
sure refractory to iridotomy are further possible mechanisms of malignant glaucoma 
as proposed by Quigley et al.8 These features lead to aqueous misdirection into the 
vitreous cavity restricted by the anterior hyaloid membrane and additional forward 
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movement of the lens–iris diaphragm.9,10 It is clinically char-
acterized by an axial shallowing of the anterior chamber in the 
absence of a pupillary block mechanism, choroidal effusion, 
or hemorrhage, despite the presence of a patent iridectomy.11 
Intraocular pressure (IOP) is usually dramatically increased, 
but may also be within the normal range.12 Treatment of 
malignant glaucoma should be done stepwise. Medical 
treatment includes topical antiglaucomatous medication, 
cycloplegic agents, aqueous suppressants, systemic carbonic 
anhydrase inhibitors, and hyperosmotic drugs inducing a 
posterior movement of the lens–iris diaphragm, reducing 
production of aqueous humor, and dehydrating the vitreous 
volume.13 The performance of laser capsulotomy,14 or laser 
anterior hyaloidectomy,15 and argon laser of ciliary processes 
through a peripheral iridectomy16 to relieve the ciliolenticular 
block are recommended for unsuccessful medical treatment. 
When medical and laser treatment failed, surgery should be 
performed to interrupt the ciliolenticular block. Pars plana 
vitrectomy in pseudophakic eyes or combined vitrectomy 
and cataract surgery in phakic eyes are effective methods to 
allow aqueous outflow into the anterior chamber.17,18 Apart 
from anterior vitrectomy alone or in combination with 
phacoemulsification17–19 or trabeculectomy20 via a posterior 
approach (pars plana), a procedure called zonulo-hyaloido-
vitrectomy through a peripheral iridectomy or iridotomy via 
the anterior chamber was described by Lois et al in 2001.21 
Due to the difficulty in visualization of the anterior hyaloid 
membrane in phakic eyes and the risk of damaging the lens, 
Chen et al published a new technique of videoendoscope-
guided fluorescein-assisted vitrectomy in phakic eyes.22
In this study, a series of patients diagnosed with malignant 
glaucoma, who underwent pars plana vitrectomy to interrupt 
the ciliolenticular block mechanism, were reviewed. Major 
outcome measures were the event preceding malignant 
glaucoma, the efficacy of vitrectomy including success rate 
based on IOP reduction and need for medical treatment, and 
complications following vitrectomy in eyes with and without 
previous trabeculectomy.
Material and methods
Patients
Clinical records of 15 patients were reviewed retrospec-
tively undergoing pars plana vitrectomy for treatment of 
malignant glaucoma at the University Eye Hospital of 
Wuerzburg, Germany between 1995 and 2010. The follow-
ing parameters were recorded: age, sex, lens status, primary 
ophthalmic diagnosis, past medical history, glaucoma 
medication, and the event preceding malignant glaucoma. 
Preoperatively, all patients received a standard ophthalmic 
examination including best corrected visual acuity measure-
ment, applanation tonometry, slit lamp biomicroscopy, and 
indirect ophthalmoscopy.
Clinical inclusion criteria of malignant glaucoma were 
as follows: shallow anterior chamber in the presence of a 
patent iridectomy or iridotomy after a choroidal hemorrhage 
or effusion have been ruled out. Most of the patients had an 
increased IOP at the onset of malignant glaucoma. However, 
three patients were included according to the inclusion cri-
teria despite having an IOP , 20 mmHg.
Patients were divided into a group with (Trab group) and 
one without (nonTrab group) previous trabeculectomy to 
evaluate the influence of vitrectomy on success of patients 
who had undergone filtration surgery before.
Success was defined as an IOP # 21 mmHg and IOP 
reduction by $20% (definition one) or an IOP , 18 mmHg 
to baseline measures (definition two) with (qualified success) 
and without (complete success) IOP-lowering medication.
Surgical technique
Prior to surgical treatment, neodymium:yttrium-aluminium-
garnet (Nd:YAG) laser iridotomy was performed in all 
patients of the nonTrab group to rule out a pupillary block. Of 
these, three patients required additional surgical iridectomy 
for inconsistent iridotomy. As intensive medical treatment 
(including cycloplegic agents and topical and systemic 
IOP-lowering medication) remained unsuccessful and IOP 
was persistently elevated, pars plana vitrectomy became a 
prerequisite. A 20-gauge port was used in six patients of 
the Trab group and in all six patients of the nonTrab group 
and a 23-gauge port in three patients of the Trab group. 
Anterior vitrectomy via pars plana was performed using a 
three-port technique to disrupt the anterior hyaloid membrane 
ensuring aqueous outflow from the vitreous cavity into the 
anterior chamber in order to interrupt the ciliolenticular 
block mechanism. Existing adhesions and remnants of the 
vitreous body around the peripheral iridectomy were removed 
to allow patency for anterior aqueous flow. Vitrectomy was 
continued until the anterior chamber deepened. In phakic eyes 
with significant cataract, combined vitrectomy and cataract 
extraction were performed.
Data analysis
SPSS® version 19.0 for Windows (IBM Corporation, Armonk, 
NY, USA) was used for statistical analyses and to create 
figures. Categorical variables were evaluated with Pearson’s 
chi-squared test or Fisher’s exact test. Differences between 
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groups in single discrete variables of nonnormal distribution 
were tested for significance using the Mann–Whitney U 
test for small sample sizes. A maximum two-tailed P-value 
of ,0.05 was considered an indication of statistical 
significance.
Results
The results of 15 patients undergoing anterior vitrectomy 
for treatment of malignant glaucoma during a 12-month 
follow-up are described.
Baseline data
Nine patients (Trab group) developed a ciliolenticular block 
following filtration surgery with a patent iridectomy in the 
absence of a pupillary block, hypotony, choroidal effusion 
or hemorrhage (Table 1). In six patients (nonTrab group), 
several intraocular surgeries, laser, or cyclodestructive 
treatments were performed prior to malignant glaucoma 
(Table 2). Malignant glaucoma occurred in seven patients 
after trabeculectomy and in two patients after combined 
trabeculectomy and cataract extraction. The median time 
between filtration surgery and malignant glaucoma was 
41.4 days (range: 5–205 days). Of the patients in the non-
Trab group, one patient developed a ciliolenticular block 
after neodymium:yttrium-aluminium-garnet (Nd:YAG) laser 
peripheral iridotomy five patients after cataract surgery. 
Mean time to malignant glaucoma was 14.0 days (range: 
1–41 days) with one patient, who had a cataract extraction 
9 years prior, excluded.
The mean age of six female and three male patients in the 
Trab group was 65 years (range: 41–88 years). Four women 
and two men with a mean age of 78 years (range: 61–85 years) 
were included in the nonTrab group and were significantly 
older than patients with filtering blebs (P = 0.046). Patients in 
Table 1 Characteristics of nine patients with previous trabeculectomy (Trab group) undergoing vitrectomy for malignant glaucoma
Patient/  
sex/ age/ 
eye
Axial  
length  
(mm)
Pseudo- 
phakic
Procedure  
prior to  
malignant  
glaucoma
Time to  
malignant  
glaucoma  
(days)
Baseline Last visit Follow-
up 
(months)
IOP  
(mmHg)
BCVA  
(logMAR)
IOP  
(mmHg)
BCVA  
(logMAR)
1/f/75/r – Yes Trab 6 16 3.00 13 3.00 7 days
2/f/60/L 21.16 Yes Phaco-Trab 13 24 0.40 18 0.10 37
3/f/58/r 21.07 Yes Phaco-Trab 17 23 0.70 14 0.20 13
4/f/73/r 21.20 Yes Trab 31 20 1.30 12 0.50 6
5/f/41/L 21.31 no Trab 205 23 0.70 22 0.70 11
6/m/49/L 23.32 no Trab 18 13 2.00 15 1.30 12
7/m/64/L 22.63 no Trab 5 44 1.30 11 0.40 58
8/f/88/L – Yes Trab 5 30 3.00 22 3.00 14 days
9/m/73/L 22.95 no Trab 36 32 3.00 21 1.20 25
Abbreviations: Trab, trabeculectomy; Phaco-Trab, combined trabeculectomy and phacoemulsification with posterior chamber intraocular lens implantation.
both groups had a median axial length of 22.0 ± 1.0 mm and 
22.5 ± 1.0 mm (P = 0.383) with a median lens thickness of 
4.8 ± 0.9 mm and 4.6 ± 0.7 mm (P = 0.800), respectively.
Five patients in the Trab group and all the patients in the 
nonTrab group were pseudophakic at the time of diagnosing 
malignant glaucoma. Two phakic patients of the Trab group 
had combined cataract extraction while performing vitrec-
tomy. Indications for combined surgery were a significant 
cataract and failed deepening of the anterior chamber during 
vitrectomy.
iOP
The mean IOP of patients in the Trab group was 25.0 ± 
9.3 mmHg at the time of malignant glaucoma and was lower 
than in patients of the nonTrab group (38.8 ± 21.0 mmHg), 
although no statistical difference was found (P = 0.135). 
Figure 1 illustrates IOP development during follow-up 
for both groups. A reduction in IOP was observed after 
12 months compared to baseline IOP for both groups. IOP was 
20.0 ± 3.9 mmHg in the Trab group and 20.3 ± 3.3 mmHg in 
the nonTrab group at the 12-month visit. No statistical differ-
ence in IOP was found between the two groups (P = 0.571).
Medication
Preoperatively, patients of the Trab group received a total 
number of 2.0 ± 1.3 (range one to four) topical agents. Pre-
operatively, patients of the nonTrab group needed 3.0 ± 1.3 
(range two to five) topical IOP-lowering drugs. Additional 
systemic medication (acetazolamide, mannitol) was neces-
sary in all patients of both groups to lower IOP. The number 
of patients with IOP-lowering medication dropped to two 
patients in the Trab group needing 2.0 ± 1.4 medication after 
1 month. One patient in the nonTrab group was on 4.0 topical 
medications at the 1-month visit. However, seven patients in 
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Figure 1 Development of intraocular pressure in patients with and without trabeculectomy prior to malignant glaucoma. reduction of postoperative intraocular pressure 
was obtained during follow-up. Intraocular pressure was not statistically significant different between the two groups during follow-up.
Notes: Box plots illustrate the median (50th percentile) as a black center line and the 25th and 75th percentile as the lower and upper hinges of the box; circles represent 
minor outliers; stars represent major outliers.
Abbreviations: iOP, intraocular pressure; Trab, trabeculectomy.
Table 2 Characteristics of six patients without previous trabeculectomy (nonTrab group) undergoing vitrectomy for malignant 
glaucoma
Patient/ 
sex/age/ 
eye
Axial 
length 
(mm)
Pseudo-
phakic
Procedure 
prior to  
malignant  
glaucoma
Time to  
malignant  
glaucoma  
(days)
Baseline Last visit Follow-
up 
(months)
IOP  
(mmHg)
BCVA  
(logMAR)
IOP  
(mmHg)
BCVA  
(logMAR)
1/f/83/r 21.93 Yes Phaco† –† 40 3.00 21 3.00 12 days
2/f/77/L – Yes Phaco 9 30 1.30 10 1.30 13
3/f/61/r 21.87 Yes nd:YAG i 6 16 0.70 19 0.50 15
4/f/81/r 23.55 Yes Phaco 41 31 1.50 25 1.00 31
5/m/80/L – Yes Phaco 1 78 3.00 8 1.30 1
6/m/85/r – Yes Phaco 13 38 1.30 20 3.00 23
Note: †Cataract extraction was performed 9 years prior to malignant glaucoma.
Abbreviations: Phaco, phacoemulsification with posterior chamber intraocular lens implantation; Nd:YAG I, neodymium:yttrium-aluminium-garnet laser iridotomy.
Success
According to the criteria for qualified success, two (40.0%) 
patients in the Trab group fulfilled both criteria of qualified 
success after 12 months (follow-up rate 55.6%). None of 
the patients in the nonTrab group had an IOP # 21 mmHg 
and $20% reduction of IOP from baseline or an IOP 
the Trab group received a total of 2.3 ± 0.8 medications and 
four patients in the nonTrab group received 2.5 ± 1.0 medica-
tions at the last available visit of each patient (range: 7 days 
to 58 months). No statistical difference concerning pre- and 
postoperative IOP-lowering medication was found between 
the two groups during follow-up (P = 0.781).
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, 18 mmHg with or without IOP-lowering medication 
(follow-up rate 33.3%). Statistical analyses revealed no 
significant differences between the two groups (Table 3).
Complete success rate was 20.0% (one patient) accord-
ing to both definitions (IOP # 21 mmHg and $20% IOP 
reduction; IOP , 18 mmHg) in the Trab group at the 
12-month visit (follow-up rate 55.6%). In the nonTrab 
group, none of the patients had complete success (follow-up 
rate 33.3%). There was no statistical difference in complete 
success found between the two groups during follow-up 
(Table 3).
Complications and further interventional 
management
Pars plana vitrectomy was successful in terminating malig-
nant glaucoma and facilitated intraoperative deepening of the 
anterior chamber in all cases. The incidence of complications 
and surgical revisions are shown in Table 4.
Three of nine patients (33.3%) in the Trab group had 
transient hypotony (defined as an IOP , 5 mmHg) for a 
mean duration of 3.3 ± 3.2 days (range: 1–7 days). Of these, 
the 23-gauge approach was used for vitrectomy in two 
patients. All three patients with filtering blebs suffering from 
hypotony had a choroidal detachment for a duration ranging 
3–9 days. Postoperative hypotony lasting . 10 days without 
choroidal detachment was seen in one patient (16.7%) of the 
nonTrab group. There was no statistical difference in length 
of hypotony between both groups (P = 0.500). In four patients 
(44.4%) of the Trab group, anterior chamber flattened again 
for 1–7 days postoperatively and deepened spontaneously 
thereafter without further interventions. In contrast, in two 
patients (33.3%) of the nonTrab group, the anterior chamber 
was shallow for 3 days after vitrectomy, deepened spontane-
ously, and remained deep thereafter. Further adverse events 
were failure of filtering blebs in four patients and progression 
of cataract in two patients of the Trab group. Neither  choroidal 
effusion, blebitis, endophthalmitis, nor iris incarceration was 
seen in either group during follow-up.
Incidence of further surgical interventions including 
cyclodestructive procedures and revitrectomy is summa-
rized in Table 4. In five patients (55.6%) of the Trab group 
and in three patients (50%) of the nonTrab group, one or 
more additional IOP-lowering procedures were necessary. 
In three patients of the Trab group, four diode cyclophoto-
coagulations and cyclocryocoagulations were performed, 
Table 3 Baseline data and outcomes of success at 6 and 12 
months after pars plana vitrectomy
Trab  
group
nonTrab  
group
P-value
Preoperative 
iOP (mmhg) 
number of iOP-lowering 
medication 
number of patients with 
medication (%)
 
25.0 ± 9.3 
2.0 ± 1.3 
 
9 (100.0)
 
38.8 ± 21.0 
3.0 ± 1.3 
 
6 (100.0)
 
0.135‡ 
0.130‡
At 6 months 
number of patients (%) 
iOP (mmhg) 
Qualified success [n (%)] 
 # 21 mmhg + 20% iOP ↓ 
 , 18 mmhg 
number of iOP-lowering 
medication 
number of patients with 
medication (%) 
Complete success [n (%)] 
 # 21 mmhg + 20% iOP ↓ 
 , 18 mmhg
 
5 (55.6) 
18.0 ± 7.8 
 
3 (60.0) 
3 (60.0) 
3.3 ± 1.5 
 
3 (60.0) 
 
 
2 (40.0) 
2 (40.0)
 
3 (50.0) 
18.0 ± 5.6 
 
2 (66.7) 
1 (33.3) 
3.5 ± 2.1 
 
2 (66.7) 
 
 
1 (33.3) 
0 (0.0)
 
 
0.732‡ 
 
1.000† 
0.604† 
1.000‡ 
 
 
 
 
1.000† 
0.486†
At 12 months 
number of patients (%) 
iOP (mmhg) 
Qualified success [n (%)] 
 # 21 mmhg + 20% iOP ↓ 
 , 18 mmhg 
number of iOP-lowering 
medication 
number of patients with 
medication (%) 
Complete success [n (%)] 
 # 21 mmhg + 20% iOP ↓ 
 , 18 mmhg
 
5 (55.6) 
20.0 ± 3.9 
 
2 (40.0) 
2 (40.0) 
2.8 ± 1.3 
 
4 (80.0) 
 
 
1 (20.0) 
1 (20.0)
 
2 (33.3) 
20.3 ± 3.3 
 
0 (0) 
0 (0) 
4.0 ± 2.8 
 
2 (100.0) 
 
 
0 (0) 
0 (0)
 
 
0.571† 
 
0.486† 
0.486† 
0.800‡ 
 
 
 
 
1.000† 
1.000†
Notes: †Pearson´s chi-squared test (Fisher´s exact test); ‡Mann-Whitney U test; 
values are means ± standard deviation unless otherwise stated.
Abbreviations: iOP, intraocular pressure; Trab, trabeculectomy.
Table 4 incidence of postoperative complications and further 
interventions
Trab  
group
nonTrab  
group
P-value†
hypotony (,5 mmhg)
 Duration (range)
3 (33.3)
1–7 days
1 (16.7)
10 days
0.604
0.500
Shallow anterior chamber 4 (44.4) 2 (33.3) 1.000
Choroidal detachment
 Duration (range)
3 (33.3)
3–9 days
–
–
0.229
Corneal decompensation 3 (33.3) 2 (33.3) 1.000
Progression of cataract 2 (22.2)# –‡ 0.486
Conjunctival leakage 1 (11.1) – 1.000
Choroidal effusion – – –
iris incarceration – – –
Blebitis/endophthalmitis – – –
Additional procedures
 Diode cyclophotocoagulation
 Cyclocryocoagulation
 revitrectomy
4 (44.4)
4 (44.4)
1 (11.1)
2 (33.3)
3 (50.0)
–
1.000
1.000
1.000
Notes: †Pearson’s chi-squared test (Fisher’s exact test); ‡all patients were 
pseudophakic at the time of vitrectomy; #two patients remained phakic after initial 
vitrectomy; data represents absolute values (percentage).
Abbreviation: Trab, trabeculectomy.
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respectively. Two patients in the nonTrab group needed 
diode cyclophotocoagulation and three patients received 
cyclocryocoagulation. No statistical difference regarding 
complications or surgical revisions was found between the 
two groups.
Discussion
Ciliolenticular block glaucoma remains one of the most 
challenging serious adverse events necessitating immediate 
treatment to reduce aqueous misdirection into the vitreous 
and consecutive displacement of the lens–iris diaphragm. 
In a recent review by Ng and Morgan, different pathophysi-
ological features are described to play an important role for 
development of ciliolenticular block glaucoma, although 
not every part is clearly understood.7 Lens disproportion 
and lens–ciliary body apposition in at-risk eyes (hyperopic, 
nanophthalmic) and anterior hyaloid changes with increased 
hydraulic resistance due to a strong adhesion between vitre-
ous, lens, and ciliary body are major pathogenic factors.7 
In angle closure eyes, the lens is disproportionally large 
and increases in size, thereby pushing the iris and ciliary 
body forwards. In addition, as the lens–ciliary body dis-
tance decreases, the fluid resistance increases and aqueous 
humor passes through the anterior vitreous restricted by the 
anterior hyaloid. Moreover, lens apposition to the ciliary 
body may lead to reduced aqueous flow into the anterior 
chamber. Both lens disproportion and lens–ciliary body 
apposition result in forward movement of the lens–iris dia-
phragm and a shallow anterior chamber.7 Since malignant 
glaucoma also occurs in aphakic eyes, the lens seems not to 
be the only cause. Flow resistance increases as the aqueous 
humor passes through the vitreous body and compresses 
the anterior hyaloid face. The pressure differential between 
the anterior and  posterior chamber leads to an anterior dis-
placement of iris and ciliary body. Quigley et al described 
poor vitreous flow and a tendency towards expansion of the 
choroidal volume in small eyes with angle closure refrac-
tory to iridotomy as possible mechanisms of malignant 
glaucoma.8
Anterior vitrectomy for malignant glaucoma refractory 
to medical and laser treatment facilitates aqueous humor 
outflow into the anterior chamber and reflects one recogniz-
ing pathophysiologic role of the vitreous in the mechanism 
of malignant glaucoma.7,23,24 Results of vitrectomy in pseu-
dophakic and aphakic eyes developing malignant glaucoma 
have been published in several previous studies.18–22,25,26 
Nevertheless, vitrectomy alone in phakic eyes may be disap-
pointing due to the difficulty in visualization and removal of 
the anterior hyaloid membrane without lens damaging.18,25,26 
Therefore, combined cataract extraction and vitrectomy 
even in eyes without lens opacities or mild lens opacities 
are strongly recommended.
In this study of 15 patients diagnosed with malignant 
glaucoma, the efficacy and safety of pars plana vitrectomy 
for treatment of the ciliolenticular block was evaluated. 
The results were based on data of patients with and without 
previous filtration surgery during a median follow-up of 
16.4 months. It was found that vitrectomy for malignant glau-
coma was successful in IOP reduction after medical treatment 
failed. Vitrectomy seems to be effective in patients with and 
without previous trabeculectomy with adequate reduction 
of IOP, although IOP-lowering medication is necessary in 
nearly all cases to maintain desired IOP.
Byrnes et al reported on a case series report of 20 
patients with malignant glaucoma and success of vitrec-
tomy in 50% of phakic patients and 90% of pseudophakic 
eyes.18 They recommended combined vitrectomy and 
crystalline lens extraction to allow removal of the entire 
anterior vitreous without damaging the lens. They defined 
success as immediate backward movement of the iris–
lens diaphragm during vitrectomy recovering the aqueous 
outflow, and deepening of the anterior chamber. This is in 
contrast to the current study in which success was based on 
criteria of IOP reduction and medication use. Although the 
anterior chamber deepened after vitrectomy in all cases of 
the current study, medication or subsequent IOP-lowering 
procedures became necessary in the majority of patients 
to reach target IOP.
A study by Harbour et al, in which surgical outcomes 
of vitrectomy of ten pseudophakic and 14 phakic eyes were 
compared, revealed a successful initial vitrectomy in 100% of 
seven phakic eyes undergoing concurrent lens extraction and 
in 71% of seven phakic eyes without cataract extraction.26 In 
pseudophakic patients, the initial vitrectomy was successful 
in 90% of patients. Therefore, lensectomy during vitrectomy 
may be considered in cases of dense cataract or inability 
to deepen the anterior chamber. In the current study, more 
than two-thirds of patients were pseudophakic at the time of 
vitrectomy, whereas two patients received cataract extrac-
tion during vitrectomy. Thus, two patients remained phakic 
and also had a successful IOP reduction after deepening of 
the anterior chamber, but showed a progression of cataract 
during follow-up.
In the current study, the 23-gauge transconjunctival 
sutureless vitrectomy was equally effective compared to the 
standard three-port 20-gauge system regarding reduction of 
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IOP and success rate. While the 23-gauge approach is fre-
quently associated with a higher incidence of postoperative 
hypotony, no differences were found in complication rates 
between both systems. Furthermore, complications were 
few in both groups. This is in line with previously pub-
lished data on complications after vitrectomy for malignant 
glaucoma mostly encountering transient shallowing of the 
anterior chamber, hypotony, retinal or choroidal detachment, 
corneal decompensation, and bleb failure needing surgical 
revision.18,26
Lois et al reported a novel technique of zonulo-hyaloido-
vitrectomy using a vitreous cutter through a peripheral 
iridectomy or iridotomy via the anterior chamber in five 
patients.21 Resolution of malignant glaucoma was achieved 
in all cases during a follow-up of 5.5 months. Lois et al stated 
that zonulo-hyaloido-vitrectomy via an anterior approach 
appears to be an option in the treatment of pseudophakic 
malignant glaucoma and can be safely done by an anterior 
segment surgeon.21
Due to the difficulty in visualization of the anterior 
hyaloid membrane in phakic eyes, Chen et al introduced 
a novel technique of videoendoscope-guided fluorescein-
assisted vitrectomy without cataract extraction in selected 
cases of prepresbyopic patients to avoid the need for clear lens 
extraction.22 However, they stated that the limited illumina-
tion field of the videoendoscope, when simultaneously used 
with the vitreous cutter, may contribute to an unintentional 
touch of the lens during vitrectomy. Previous studies have 
addressed the importance of lensectomy to achieve desired 
IOP reduction after the initial vitrectomy since pseudophakic 
eyes compared to phakic eyes show a higher success rate in 
terminating malignant glaucoma.18,19,25,26
The current study has some limitations. First, retrospec-
tive data commonly has more sources of error due to con-
founding and bias. Second, the sample size was too small to 
detect small differences between the two groups. It is difficult 
to collect a large number of cases since malignant glaucoma 
is a very rare disease. Prospective trials with greater statisti-
cal power will be needed to establish surgical methods of 
malignant glaucoma.
Conclusion
In summary, pars plana vitrectomy using the 20- and 
23-gauge approach is effective for treatment of malignant 
glaucoma in patients with and without previous filtration 
surgery. Efficacy regarding reduction of IOP, success, and 
complications rates was similar in eyes with and without 
previous trabeculectomy.
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